Disc Medicine, Inc.

Disc Medicine, Inc. (Nasdaq: GMTX) is a clinical-stage biopharmaceutical company focused on hematologic diseases that entered the public markets via a de-SPAC transaction. The company traces its public listing to a business combination between LifeSci Acquisition Corp, sponsored by LifeSci Capital, and Gemini Therapeutics, which closed in 2021 following the SPAC's 2020 IPO. After the combination, Gemini Therapeutics rebranded as Disc Medicine, Inc. in 2023 to better reflect its hematology-focused pipeline. The Form 8-K filed June 9, 2023 is a current report disclosure from the company's post-combination operating phase. For comprehensive SPAC filing history and analytics on GMTX, sign up for full data access at SpacDesk.